Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Cameron Turtle
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 125
- Beta
- 3.03
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 75.06
Financials
Revenue
$0.00-100.0%Net Income
$-36.20MEBITDA
$-36.20MFree Cash Flow
$-69.88MEPS (diluted)
$-0.36Shares Outstanding (diluted)
84.73M+3119.7%Operating Expenses
$81.64MCash & Debt
$1.15BReturn of Capital
$0.00Revenue by Segment (annual)
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-155.20M | $-1.98 |
| 2024 | $0.00 | $-208.02M | $-3.18 |
| 2023 | $886.0K | $-338.79M | $-46.15 |
| 2022 | $2.33M | $-83.81M | $-24.86 |
| 2021 | $18.74M | $-65.80M | $-25.02 |
| 2020 | $0.00 | $-80.89M | $-37.89 |
| 2019 | $0.00 | $-78.25M | $-61.23 |
| 2018 | $3.89M | $-44.35M | $-53.25 |
| 2017 | $5.21M | $-27.24M | $-45.01 |
| 2016 | $4.63M | $-21.70M | $-55.40 |
| 2015 | $6.08M | $-11.29M | $-24.71 |
| 2014 | $0.00 | $-10.35M | $-18.91 |
Valuation
SYREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- News (RSS)investing·20h ago·Neutral
Spyre Therapeutics stock hits 52-week high at 108.16 USD
View source ↗
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-0.80 per share
Typical surprise +11.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.36 vs $-0.76beat
- Tue, May 5$-0.74 vs $-0.66miss
- Thu, Feb 19$-0.70 vs $-0.66miss
- Tue, Nov 4$-0.15 vs $-0.76beat
- Tue, Aug 5$-0.49 vs $-0.73beat
- Thu, May 8$-0.74 vs $-0.84beat
Estimates and results for SYRE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SYRE officers and directors.
- Bought
- —
- Sold
- $429.6m
0 trades
63 trades
- Albers Jeffrey W.sold
- Albers Jeffrey W.sold
- Albers Jeffrey W.sold
- Burrows Scott Lsold
- Burrows Scott Lsold
- Burrows Scott Lsold
- Turtle Cameronsold
- Turtle Cameronsold
37 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.